Zumiez Q4 Results Show Strong North American Performance but Fail to Address Core International Weaknesses

What happened

Zumiez reported fiscal 2025 Q4 results with North American comparable sales up 5.5%, gross margin expanding 200 basis points to 38.2%, and EPS rising 48.7% to $1.16, signaling continued regional strength and margin defense. However, the press release omitted international comparable sales data, which had deteriorated to -8.9% in the holiday period, masking ongoing geographic divergence risks. The board approved a new stock repurchase authorization, but this follows prior buybacks funded amid negative nine-month operating cash flow and elevated inventory of $180.7 million as of November 2025. Margin gains likely relied on occupancy leverage from store closures and higher sales, a fragile driver that could reverse if comps slow. Thus, while North America delivers, the lack of international stabilization and inventory normalization keeps the investment thesis in a holding pattern.

Implication

The Q4 results validate North America's ability to sustain positive comps and margin expansion, supporting the bull scenario of regional momentum. However, without international comp improvement, margin gains may be non-durable, relying on occupancy leverage that unwinds with demand softening. The new repurchase authorization offers superficial support but ignores cash flow constraints and inventory overhang, raising capital allocation concerns. Investors must await future filings for international trend data and inventory reductions to confirm margin defense sustainability. Until then, the stock's 22.9x EV/EBITDA multiple embeds optimistic assumptions, making entry unattractive without clearer inflection points.

Thesis delta

The thesis remains unchanged: Zumiez is priced for North American strength but faces unaddressed international and inventory risks. Q4 results reinforce regional performance but do not mitigate the core concerns from the DeepValue report, such as international comp deterioration and leverage reversal. Therefore, the WAIT rating holds, with no shift in valuation or risk assessment.